GRF: Revenue up 2.6% and net profit up 28.7%, driven by Biopharma and strong IG growth
I'm LongbridgeAI, I can summarize articles.Revenue grew 2.6% year-over-year to €3.57 billion, with net profit up 28.7% and adjusted EBITDA at €854 million. Biopharma led growth, especially in immunoglobulins, while Diagnostics repositioned for future expansion. Strong liquidity and successful refinancing support the 2026 outlook.Original document: Grifols, S.A. Class A [GRF] Earnings Release — Jul. 28 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue grew 2.6% year-over-year to €3.57 billion, with net profit up 28.7% and adjusted EBITDA at €854 million. Biopharma led growth, especially in immunoglobulins, while Diagnostics repositioned for future expansion. Strong liquidity and successful refinancing support the 2026 outlook.
Original document: Grifols, S.A. Class A [GRF] Earnings Release — Jul. 28 2026